NasdaqCM · Biotechnology

Aprea Therapeutics (APRE)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+454.4%

$3.55 average target

$0.64+0.01 (+1.2%)Latest market snapshot · Yahoo Finance

Market cap$8.1M

Cash$41.2M

Quarterly burn$2.8M

Pipeline assets5

Short float0.3%

Clinical portfolio

Aprea Therapeutics Drug Pipeline

Showing 1 of 5

Asset	Indication	Stage	Milestone	Signals ?
APR-1051	Solid tumor/s, Cancer	Phase 1	Dec 31, 2026	Mgmt interest

Continue with BioPharma ProUnlock 4 additional programs and complete development details.

Unlock Pro

Upcoming milestones

APRE Catalyst Timeline

1 currently tracked

Dec 31, 2026

APR-1051

Phase 1Mgmt interest

Company profile

About Aprea Therapeutics

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.